Neurocrine Biosciences
NBIX
NBIX
454 hedge funds and large institutions have $8.66B invested in Neurocrine Biosciences in 2023 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 164 increasing their positions, 185 reducing their positions, and 69 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
454
Holders Change
-29
Holders Change %
-6%
% of All Funds
7.16%
Holding in Top 10
11
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+57.14%
% of All Funds
0.17%
New
41
Increased
164
Reduced
185
Closed
69
Calls
$51.6M
Puts
$37.7M
Net Calls
+$13.9M
Net Calls Change
+$26.6M
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$78.4M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$73.1M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$71.1M |
| 4 |
Man Group
London,
United Kingdom
|
+$59.5M |
| 5 |
IC
IEQ Capital
Foster City,
California
|
+$45.4M |
Top Sellers
| 1 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
-$86.2M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$69.9M |
| 3 |
DM
Deerfield Management
New York
|
-$50.5M |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$30.6M |
| 5 |
Renaissance Technologies
New York
|
-$28.6M |
